Overview
- FDA staff reviewers published briefing documents on Monday concluding the evidence does not support allowing compounding pharmacies to manufacture seven widely promoted peptides.
- The agency named a reconstituted Pharmacy Compounding Advisory Committee that largely includes clinicians, compounding pharmacists, and clinic operators who prescribe or sell peptides, prompting questions about conflicts of interest.
- The staff specifically recommended against adding BPC-157 and TB-500 to the approved compounding list and flagged missing human trials, unclear chemical forms, incomplete impurity and sterility data, and possible immune reactions from injections.
- Health Secretary Robert F. Kennedy Jr. has publicly endorsed peptide use and reclassified a set of peptides in April toward easier compounding access, and the committee will meet July 23–24 to issue non-binding recommendations that are likely to influence the FDA’s final decision.
- The debate matters to patients and public health because a large gray market sells peptides labeled 'for research use only,' which has led to contamination and mislabeling concerns, and past academic-heavy panels voted against compounding these substances for safety and evidence reasons.